4 articles

TED@UPS: Could Biology Cure Traffic Congestion?

What if traffic flowed through our streets as smoothly and efficiently as blood flows through our veins? Wanis Kabbaj sits down for a Q&A.
Wanis Kabbaj | UPS

In September, UPS Healthcare Strategy Director Wanis Kabbaj gave a TED@UPS talk. Longitudes caught up with him recently to talk about the experience and what he hopes people might learn from his presentation. His talk is being featured on TED.com – click the link below to view. Afterwards, check out our Q&A with Wanis below. Q. […]

Offset Cold Chain Complexities with Creativity

Pharmaceutical innovations aren’t slowing down, so why should smart logistics?
Wanis Kabbaj | UPS

In entertainment, late filmmaker Cecil B. DeMille once said, “Creativity is a drug I cannot live without.” The same can be said in healthcare about today’s 7 billion global healthcare consumers, who are living longer, have better access to quality care, and are demanding more choices, more convenience and better outcomes. It’s an evolving paradigm, […]

The New World Order in Transportation

Transportation innovation and economic growth are inextricably linked. Without innovation, economic growth is not possible.
Wanis Kabbaj | UPS

In an increasingly congested world, the transportation industry is up against unrelenting pressure to facilitate the free flow of goods. Traffic congestion in cities worldwide is a major problem. Unfortunately, the issue is compounding as cities grow and car ownership rates increase. However, there are numerous opportunities for forward-looking companies capable of delivering solutions to […]

The High Stakes in “Cold Chain”

Market changes are driving pharmaceutical companies to consider new ways to mitigate risk in the cold chain.
Wanis Kabbaj | UPS

A growing global middle class, longer supply chains, and the launch of new, innovative healthcare products are putting more complex demands on the pharmaceutical industry’s high-stakes logistics environment. Factors such as new, temperature-sensitive biologics, increasing cold-chain regulations, and growing cost pressures require pharmaceutical executives to reconsider how they prioritize “cold” supply-chain decisions. Strategies such as […]